PMID- 35123117
OWN - NLM
STAT- MEDLINE
DCOM- 20220405
LR  - 20220531
IS  - 2666-6367 (Electronic)
IS  - 2666-6367 (Linking)
VI  - 28
IP  - 4
DP  - 2022 Apr
TI  - Real-World Eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy 
      in Large B Cell Lymphoma: A Population-Based Analysis.
PG  - 218.e1-218.e4
LID - S2666-6367(22)00052-5 [pii]
LID - 10.1016/j.jtct.2022.01.024 [doi]
AB  - The ZUMA-7 trial demonstrated the superiority of second-line chimeric antigen 
      receptor (CAR) T cell therapy over standard of care chemotherapy with or without 
      autologous stem cell transplantation (ASCT) for relapsed/refractory (r/r) large B 
      cell lymphoma (LBCL). We conducted a retrospective population-based analysis to 
      determine eligibility for second-line CAR-T cell therapy in the real-world 
      setting. Among 125 patients with r/r LBCL between 2015 and 2019, 82% progressed 
      within 12 months of first-line chemoimmunotherapy (CIT), 40% were treated with 
      intention-to-transplantation, 22% underwent ASCT, and 7% achieved a durable 
      remission after ASCT. With a median follow-up of 2.8 years, the median overall 
      survival (OS) was 5.1 months, and 3-year OS was 15% (95% confidence interval 
      [CI], 7% to 20%) for all patients and 10% (95% CI, 5% to 17%) for those 
      progressing within 12 months of CIT. Although only 14% of patients met all the 
      ZUMA-7 study inclusion criteria, as many as 65% of patients progressing within 12 
      months of CIT had adequate performance status to be considered potentially 
      eligible for second-line CAR T cell therapy. Whereas the current standard of care 
      results in poor outcomes for most patients with r/r LBCL, the use of CAR T cell 
      therapy in second-line therapy could substantially increase the proportion of 
      patients able to receive curative-intent treatment at first progression of LBCL.
CI  - Copyright (c) 2022 The American Society for Transplantation and Cellular Therapy. 
      Published by Elsevier Inc. All rights reserved.
FAU - Puckrin, Robert
AU  - Puckrin R
AD  - University of Calgary and Tom Baker Cancer Centre, Calgary, Alberta, Canada. 
      Electronic address: robert.puckrin@ahs.ca.
FAU - Stewart, Douglas A
AU  - Stewart DA
AD  - University of Calgary and Tom Baker Cancer Centre, Calgary, Alberta, Canada.
FAU - Shafey, Mona
AU  - Shafey M
AD  - University of Calgary and Tom Baker Cancer Centre, Calgary, Alberta, Canada.
LA  - eng
PT  - Journal Article
DEP - 20220202
PL  - United States
TA  - Transplant Cell Ther
JT  - Transplantation and cellular therapy
JID - 101774629
RN  - 0 (Receptors, Chimeric Antigen)
SB  - IM
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Immunotherapy, Adoptive
MH  - *Lymphoma, Large B-Cell, Diffuse/therapy
MH  - *Receptors, Chimeric Antigen/therapeutic use
MH  - Retrospective Studies
MH  - Transplantation, Autologous
OTO - NOTNLM
OT  - Autologous stem cell transplantation
OT  - CAR T cell therapy
OT  - Large B cell lymphoma
OT  - Relapsed
EDAT- 2022/02/06 06:00
MHDA- 2022/04/06 06:00
CRDT- 2022/02/05 20:13
PHST- 2021/12/21 00:00 [received]
PHST- 2022/01/13 00:00 [revised]
PHST- 2022/01/28 00:00 [accepted]
PHST- 2022/02/06 06:00 [pubmed]
PHST- 2022/04/06 06:00 [medline]
PHST- 2022/02/05 20:13 [entrez]
AID - S2666-6367(22)00052-5 [pii]
AID - 10.1016/j.jtct.2022.01.024 [doi]
PST - ppublish
SO  - Transplant Cell Ther. 2022 Apr;28(4):218.e1-218.e4. doi: 
      10.1016/j.jtct.2022.01.024. Epub 2022 Feb 2.